TY - JOUR
T1 - Cytotoxic T-lymphocyte antigen 4 polymorphisms and breast cancer susceptibility
T2 - Evidence from a meta-analysis
AU - Chang, Hao Yun
AU - Liu, Chao Yu
AU - Lo, Yen Li
AU - Chiou, Shih Hwa
AU - Lu, Kai Hsi
AU - Lee, Ming Cheng
AU - Wang, Yuan Hung
N1 - Funding Information:
This work was supported by grants from the Ministry of Science and Technology College Student Research Program (110-2813-C-038-132-B), Far Eastern Memorial Hospital National Yang Ming Chiao Tung University Joint Research Program (FEMH-NYCU 108DN13 and 107DN09), and Cheng-Hsin General Hospital (CY11012, CY10934, and CY10813).
Publisher Copyright:
© 2023 Wolters Kluwer Health. All rights reserved.
PY - 2023/2/1
Y1 - 2023/2/1
N2 - Background: Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is an immune checkpoint and regulates the immune function of T cells. However, previous findings regarding the association of CTLA-4 polymorphisms and breast cancer remain inconclusive. Therefore, we performed a meta-analysis to investigate the potential effects of five polymorphisms (-1722 T/C, -1661 A/G -318 C/T, +49 A/G, and CT60 A/G) in the CTLA-4 gene on breast cancer susceptibility. Methods: Relevant literatures were systematically searched through electronic databases including PubMed, EMBASE, and Web of Science up to October 10, 2021. Available data were extracted and odds ratios (ORs) with 95% confidence intervals were used to estimate the pooling effect size. The Newcastle-Ottawa Scale was applied for assessing the quality of included studies. We conducted subgroup analyses based on ethnicity and control sources to explore levels of heterogeneity. Moreover, sensitivity analysis and publication bias were assessed. Results: Finally, a total of 12 eligible studies regarding CTLA-4 polymorphisms and breast cancer were included. For overall analyses, only the +49 A/G polymorphism was significantly associated with breast cancer under allelic (OR = 1.19), dominant (OR = 1.27), and recessive (OR = 1.27) models. Ethnicity-based subgroup analysis found that the +49 A/G polymorphism has a significant risk (OR = 2.03) of breast cancer under the recessive model in the non-Asian population. Studies with hospital-based controls showed that the +49 A/G polymorphism has significant breast cancer risks under allelic (OR = 1.44), dominant (OR = 1.86), and recessive (OR = 1.60) models. In addition, those with population-based controls found that -1722 T/C polymorphism has a significant breast cancer risk under allelic (OR = 1.19) and dominant (OR = 1.26) models. Conclusion: This meta-analysis suggested that CTLA-4 + 49 A/G polymorphism may significantly associate with breast cancer susceptibility. Future studies containing various populations are helpful for evaluating the impacts of CTLA-4 polymorphisms on breast cancer susceptibility.
AB - Background: Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is an immune checkpoint and regulates the immune function of T cells. However, previous findings regarding the association of CTLA-4 polymorphisms and breast cancer remain inconclusive. Therefore, we performed a meta-analysis to investigate the potential effects of five polymorphisms (-1722 T/C, -1661 A/G -318 C/T, +49 A/G, and CT60 A/G) in the CTLA-4 gene on breast cancer susceptibility. Methods: Relevant literatures were systematically searched through electronic databases including PubMed, EMBASE, and Web of Science up to October 10, 2021. Available data were extracted and odds ratios (ORs) with 95% confidence intervals were used to estimate the pooling effect size. The Newcastle-Ottawa Scale was applied for assessing the quality of included studies. We conducted subgroup analyses based on ethnicity and control sources to explore levels of heterogeneity. Moreover, sensitivity analysis and publication bias were assessed. Results: Finally, a total of 12 eligible studies regarding CTLA-4 polymorphisms and breast cancer were included. For overall analyses, only the +49 A/G polymorphism was significantly associated with breast cancer under allelic (OR = 1.19), dominant (OR = 1.27), and recessive (OR = 1.27) models. Ethnicity-based subgroup analysis found that the +49 A/G polymorphism has a significant risk (OR = 2.03) of breast cancer under the recessive model in the non-Asian population. Studies with hospital-based controls showed that the +49 A/G polymorphism has significant breast cancer risks under allelic (OR = 1.44), dominant (OR = 1.86), and recessive (OR = 1.60) models. In addition, those with population-based controls found that -1722 T/C polymorphism has a significant breast cancer risk under allelic (OR = 1.19) and dominant (OR = 1.26) models. Conclusion: This meta-analysis suggested that CTLA-4 + 49 A/G polymorphism may significantly associate with breast cancer susceptibility. Future studies containing various populations are helpful for evaluating the impacts of CTLA-4 polymorphisms on breast cancer susceptibility.
KW - Breast cancer
KW - Cytotoxic T-lymphocyte antigen 4
KW - Immune checkpoint
KW - Meta-analysis
KW - Polymorphism
UR - http://www.scopus.com/inward/record.url?scp=85146485926&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85146485926&partnerID=8YFLogxK
U2 - 10.1097/JCMA.0000000000000851
DO - 10.1097/JCMA.0000000000000851
M3 - Article
C2 - 36652567
AN - SCOPUS:85146485926
SN - 1726-4901
VL - 86
SP - 207
EP - 219
JO - Journal of the Chinese Medical Association
JF - Journal of the Chinese Medical Association
IS - 2
ER -
